Corbus Pharmaceuticals Holdings, INC

Corbus Pharmaceuticals Holdings, Inc. announced the appointment of Leonardo Viana Nicacio, M.D., as its new Chief Medical Officer, effective August 3, 2026.

Corbus Pharmaceuticals announced updated Phase 1/2 clinical data for its CRB-701 drug, showing robust activity in oropharyngeal and cervical cancers, with plans for registrational trials.

Corbus Pharmaceuticals Holdings, Inc. announced the appointment of Nishant Saxena as Chief Business Officer and scheduled a conference call to discuss clinical data for its CRB-701 study.

Corbus Pharmaceuticals Holdings, Inc. announced the appointment of Brent Pfeiffenberger to its Board of Directors and the approval of an amendment to its 2024 Equity Compensation Plan.

Corbus Pharmaceuticals announced its Q1 2026 financial results, highlighting progress in its oncology and obesity programs with key data readouts and regulatory milestones anticipated.

Corbus Pharmaceuticals Holdings, Inc. has entered into amended and restated employment agreements with its CEO and CFO.

Corbus Pharmaceuticals reported a wider net loss for Q1 2026 due to increased R&D spending on its oncology and obesity drug candidates, while cash reserves remain sufficient for at least twelve months.

Corbus Pharmaceuticals reports increased R&D expenses and net losses in Q3 2025, while securing significant capital through recent offerings to fund its clinical pipeline.

Corbus Pharmaceuticals reports a significant increase in net loss for Q2 2025, driven by accelerated research and development spending on its oncology and obesity pipeline.

Corbus Pharmaceuticals reports a net loss of $16.98 million for Q1 2025, with increased R&D spending reflecting progress in its oncology and obesity pipeline.

Corbus Pharmaceuticals reports a net loss for Q3 2024, but highlights significant clinical advancements and a strong cash position following recent financing activities.

Corbus Pharmaceuticals reports a significant increase in cash and investments, alongside advancements in their clinical programs for cancer and obesity treatments in the second quarter of 2024.

Corbus Pharmaceuticals details its 2024 financial performance and outlines progress in its oncology and obesity drug development programs.

Corbus Pharmaceuticals has filed an amendment to its annual report to include previously omitted information regarding executive compensation and related certifications.

Corbus Pharmaceuticals' 2023 annual report highlights progress in its oncology and obesity pipelines, including clinical trial advancements and regulatory clearances, alongside significant financial losses.

Corbus Pharmaceuticals Director Winston Kung sold 2,026 shares of common stock via a pre-arranged Rule 10b5-1 trading plan.

Corbus Pharmaceuticals director Anne Altmeyer sold 2,412 shares of common stock for a weighted average price of $7.9137 per share under a pre-arranged 10b5-1 trading plan.

Chief Business Officer Nishant Saxena acquired 13,500 shares of Corbus Pharmaceuticals common stock through open market purchases.

Chief Business Officer Nishant C. Saxena was granted 58,300 restricted stock units and 192,300 stock options by Corbus Pharmaceuticals.

Director Winston Kung was granted 3,800 restricted stock units and 12,300 stock options by Corbus Pharmaceuticals.

Director Rachelle Jacques received a grant of 3,800 restricted stock units and 12,300 stock options.

Corbus Pharmaceuticals Holdings, Inc. is holding its Annual Meeting of Stockholders on May 13, 2026, to vote on key proposals including an increase in authorized shares for its 2024 Equity Compensation Plan.

Corbus Pharmaceuticals Holdings, Inc. has filed a definitive proxy statement with the SEC.

Corbus Pharmaceuticals Holdings will hold its annual meeting of stockholders virtually on May 15, 2025, to vote on director elections, auditor ratification, and executive compensation.

Corbus Pharmaceuticals has issued a supplement to its proxy statement clarifying voting standards for proposals and detailing amended employment agreements for its CEO and CFO.

Corbus Pharmaceuticals Holdings, Inc. has filed a definitive proxy statement with the SEC.

Corbus Pharmaceuticals Holdings is asking stockholders to approve the 2024 Equity Compensation Plan and authorize 2,000,000 shares for issuance.

Octagon Capital Advisors LP, Octagon Investments Master Fund LP, and Ting Jia have jointly filed a Schedule 13G, reporting no beneficial ownership of Corbus Pharmaceuticals Holdings, Inc. common stock as of March 31, 2026.

Octagon Capital Advisors LP, along with Octagon Investments Master Fund LP and Ting Jia, reported a 5.4% beneficial ownership stake in Corbus Pharmaceuticals Holdings, Inc. as of December 31, 2025.

abrdn Inc. and its parent Aberdeen Group plc have reported a beneficial ownership of 7.53% in Corbus Pharmaceuticals Holdings, Inc. common stock.

Cormorant Asset Management and Bihua Chen have disclosed a 13.36% beneficial ownership stake in Corbus Pharmaceuticals Holdings, Inc. common stock.

Cormorant Asset Management, LP and Bihua Chen have disclosed a 12.82% beneficial ownership stake in Corbus Pharmaceuticals Holdings, Inc., holding 2,375,000 shares.

Citadel and its affiliates, including Kenneth Griffin, have disclosed a combined beneficial ownership of 5.3% in Corbus Pharmaceuticals Holdings, Inc.